122 related articles for article (PubMed ID: 36974779)
1. Identification of Atezolizumab Plus Bevacizumab Prognostic Index
Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Pressiani T; Piscaglia F; Kumada T; Rimassa L; Scartozzi M; Cascinu S; Casadei-Gardini A;
Anticancer Res; 2023 Apr; 43(4):1599-1610. PubMed ID: 36974779
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
3. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
4. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.
Bannaga A; Arasaradnam RP
World J Gastroenterol; 2020 Sep; 26(33):5022-5049. PubMed ID: 32952347
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization.
Liu Y; Cheng C; Zhou H; Hu S; Wang H; Xie Q; Lei L; Wang P; Liu G; Hu H
Bull Cancer; 2021 Oct; 108(10):931-939. PubMed ID: 34247763
[TBL] [Abstract][Full Text] [Related]
7. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
Kudo M; Galle PR; Brandi G; Kang YK; Yen CJ; Finn RS; Llovet JM; Assenat E; Merle P; Chan SL; Palmer DH; Ikeda M; Yamashita T; Vogel A; Huang YH; Abada PB; Yoshikawa R; Shinozaki K; Wang C; Widau RC; Zhu AX
JHEP Rep; 2021 Apr; 3(2):100215. PubMed ID: 33392490
[TBL] [Abstract][Full Text] [Related]
8. The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma.
Kornberg A; Witt U; Schernhammer M; Kornberg J; Müller K; Friess H; Thrum K
J Surg Oncol; 2019 Dec; 120(7):1126-1136. PubMed ID: 31578753
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Salani F; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Schirripa M; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Scartozzi M; Cascinu S; Casadei-Gardini A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7565-7577. PubMed ID: 36976353
[TBL] [Abstract][Full Text] [Related]
10. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM; Cheon J; D'Alessio A; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Napolitano A; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ
Eur J Cancer; 2022 Nov; 175():204-213. PubMed ID: 36148739
[TBL] [Abstract][Full Text] [Related]
11. Preoperative albumin-bilirubin grade combined with aspartate aminotransferase-to-platelet count ratio index predict outcomes of patients with hepatocellular carcinoma within Milan criteria after liver resection.
Luo H; Li C; Chen L
Biosci Trends; 2019 May; 13(2):176-181. PubMed ID: 31061272
[TBL] [Abstract][Full Text] [Related]
12. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.
Chan AW; Kumada T; Toyoda H; Tada T; Chong CC; Mo FK; Yeo W; Johnson PJ; Lai PB; Chan AT; To KF; Chan SL
J Gastroenterol Hepatol; 2016 Jul; 31(7):1300-6. PubMed ID: 26751608
[TBL] [Abstract][Full Text] [Related]
13. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.
Kudo M; Finn RS; Cheng AL; Zhu AX; Ducreux M; Galle PR; Sakamoto N; Kato N; Nakano M; Jia J; Vogel A
Liver Cancer; 2023 Oct; 12(5):479-493. PubMed ID: 37901766
[TBL] [Abstract][Full Text] [Related]
14. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
Campani C; Bamba-Funck J; Campion B; Sidali S; Blaise L; Ganne-Carrié N; Demory A; Sutter O; Larrey E; Evain M; Ghannouchi H; Wagner M; Marra F; Sutton A; Allaire M; Nault JC
Liver Int; 2023 Mar; 43(3):708-717. PubMed ID: 36444741
[TBL] [Abstract][Full Text] [Related]
15. Survival Analysis Using Albumin-Bilirubin (ALBI) Grade for Patients Treated with Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma.
Young LB; Tabrizian P; Sung J; Biederman D; Bishay VL; Ranade M; Patel RS; Nowakowski FS; Fischman AM; Lookstein RA; Kim E
J Vasc Interv Radiol; 2022 May; 33(5):510-517.e1. PubMed ID: 35150838
[TBL] [Abstract][Full Text] [Related]
16. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma.
Wang YY; Zhong JH; Su ZY; Huang JF; Lu SD; Xiang BD; Ma L; Qi LN; Ou BN; Li LQ
Br J Surg; 2016 May; 103(6):725-734. PubMed ID: 27005482
[TBL] [Abstract][Full Text] [Related]
17. Albumin-bilirubin and platelet-albumin-bilirubin grades for hepatitis B-associated hepatocellular carcinoma in Child-Pugh A patients treated with radical surgery: A retrospective observational study.
Wu B; Hu X; Jin H; Zhou L; Zhang D; Man Z; Wang Y; Yang S; Pang Q; Liu H; Cui P
Medicine (Baltimore); 2019 Oct; 98(43):e17394. PubMed ID: 31651841
[TBL] [Abstract][Full Text] [Related]
18. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals.
Casadei Gardini A; Foschi FG; Conti F; Petracci E; Vukotic R; Marisi G; Buonfiglioli F; Vitale G; Ravaioli F; Gitto S; Verucchi G; Lenzi M; Bolondi L; Mazzella G; Brillanti S; Andreone P;
Dig Liver Dis; 2019 May; 51(5):681-688. PubMed ID: 30327251
[TBL] [Abstract][Full Text] [Related]
19. Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma.
Chan AW; Chong CC; Mo FK; Wong J; Yeo W; Johnson PJ; Yu S; Lai PB; Chan AT; To KF; Chan SL
J Gastroenterol Hepatol; 2017 Jan; 32(1):221-228. PubMed ID: 27257086
[TBL] [Abstract][Full Text] [Related]
20. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Shimose S; Iwamoto H; Shirono T; Tanaka M; Niizeki T; Kajiwara M; Itano S; Yano Y; Matsugaki S; Moriyama E; Noda Y; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
Cancer Med; 2023 Jun; 12(11):12325-12335. PubMed ID: 37062077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
